Advancing Cancer Treatment Through Research & Innovation
Our research focuses on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Current Research Projects
Our current research projects are focused on developing breakthrough treatments that combine cutting-edge science with personalized patient care, pushing the boundaries of what's possible in cancer treatment.
Efficacy of Compression Therapy for Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Early Breast Cancer: Insights from a Single-Centre Experience in Bangladesh
Prospective
Research Objectives:
- • Incidence of CTCAE version 5 grade 2 or higher CIPN in both upper and lower extremities during entire period of chemotherapy.
The Efficacy of Pembrolizumab for Treatment of Early Triple Negative Breast Cancer: A Single-center, Open, Randomized Controlled Trial
Primary endpoints: A) Pathological Complete Response at the time of definitive surgery B) Event-free survival in the intention-to-treat population Secondary endpoints: Overall survival at the end of 15 months
Research Objectives:
- • A prospective study to measure the efficacy of Pembrolizumab in Early Triple Negative Breast Cancer (TNBC) patients of Bangladeshi population.
Recent Publications
Peer-reviewed research contributions published in leading oncology journals, advancing the field of cancer treatment.
PATHOLOGICAL COMPLETE RESPONSE WITH PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR NEOADJUVANT TREATMENT OF EARLY TRIPLE NEGATIVE BREAST CANCER: A SINGLECENTER PROSPECTIVE STUDY FROM BANGLADESH
This observational study is aimed to find out the Pathological Complete Response (pCR) at the time of definitive surgery who had received chemotherapy along with Pembrolizumab as neoadjuvant settings. After …
Key Findings:
Results Among the 6 patients the age range is 37-75 years and only 2 was right sided where the 4 is left sided breast primary. …
THE ROLE OF CONCOMITANT MET AMPLIFICATION AND HIGH PD-L1 EXPRESSION IN NON-SMALL CELL LUNG CANCER: A CASE REPORT OF IMPLICATIONS FOR TARGETED THERAPY AND IMMUNOTHERAPY
MET amplification occurs in approximately 1-5% of treatment-naïve non-small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase …
Key Findings:
Due to poor response with 1st line CnT, 6 cycle of 2nd line palliative ChT-IO with Atezolezumab + Pemetexed + Carboplatin + Denosumab followed by …
Characteristics of metastatic lung cancer patients on osimertinib therapy in Bangladesh
Eighty patients with metastatic lung cancer receiving osimertinib therapy were included in this descriptive cross-sectional study. This study covered patients with lung cancer metastases who were receiving osimertinib, regardless of …
Key Findings:
According to the findings, the patients' mean (±SD) age was 60.95 ±13.98 years. Patients who were between the ages of 55 and 75 had the …
Showing 1 to 3 of 19 publications
Conference Presentations & Speaking Engagements
Sharing research findings and clinical insights at leading medical conferences worldwide.
40th The Society for Immunotherapy of Cancer (SITC) 2025
Pathological complete response with Pembrolizumab in combination with chemotherapy for Neoadjuvant Treatment of Early Triple Negative Breast Cancer: A Single-center prospective study from Bangladesh.
Triple negative breast cancer is the kind of breast cancer that does not have any receptors which are usually found in breast cancer. It is estrogen- receptor, progesterone-receptor, and HER-2 receptor negative. About 10-15% of all breast cancers are triple negative. Its commonly seen in women aged than 40 years, and those have a BRCA-1 mutation. This is a more aggressive form of cancer, harder to treat and has chances of recurrences. The single most prognostic factor is still the pathological complete response in case of neoadjuvant (NACT)settings.
40th The Society for Immunotherapy of Cancer (SITC) 2025
The Role of Concomitent MET Amplification and High PD-L1 Expression in Non-Small Cell Lung Cancer: A case report of Implications for Targeted Therapy and Immunotherapy
MET amplification occurs in approximately 1-5% of treatment-naïve non- small cell lung cancer (NSCLC) cases. It can also develop as an acquired resistance mechanism, particularly after treatment with EGFR tyrosine kinase inhibitors (TKIs), where it's observed in about 15% of cases. This case underscores the coexistence of MET gene amplification and high PD-L1 expression in NSCLC, which has significant therapeutic implications. The presence of MET amplification suggests potential benefit from MET- targeted therapies, while high PD-L1 expression indicates responsiveness to immune checkpoint inhibitors. When MET amplification and high PD-L1 co-exist, the optimal treatment strategy can be challenging. The integration of molecular and immunohistochemical data guides personalized treatment strategies for this patient.
BICC 2025
The Impact of Dual vs Single Anti-HER2: A Real-World Retrospective Analysis of Treatment Outcomes in Bangladesh
30th October (Thursday) 2:00PM- 3:00PM 10 Minutes Speaker Breakthrough Research from Bangladesh
ESMO Asia 2025
Evaluating the Success of the Current Standard of Care in Breast Cancer Treatment: A Retrospective Study in Bangladesh
Background: Breast cancer is a major cause of morbidity and mortality among women, with LMICs like Bangladesh facing poorer outcomes due to late diagnoses and limited targeted therapies. This study evaluates the effectiveness of current standard-of-care breast cancer treatment in Bangladesh, focusing on luminal subtypes and survival outcomes. Methods: A retrospective review of 1,088 breast cancer patients treated at Bangladesh Specialized Hospital was conducted. Data on demographics, tumor subtype, treatment, and outcomes were analyzed. Kaplan-Meier and Cox regression models assessed progression-free survival (PFS) and overall survival (OS).
Showing 1 to 4 of 6 presentations